Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
PLoS One. 2011 Apr 11;6(4):e18365. doi: 10.1371/journal.pone.0018365.
It is generally assumed that T cells do not produce active TGF-β since active TGF-β as measured in supernatants by ELISA without acidification is usually not detectable. However, it is possible that active TGF-β from T cells may take a special form which is not detectable by ELISA.
METHODOLOGY/PRINCIPAL FINDINGS: We constructed a TGF-β bioassay which can detect both soluble and membrane-bound forms of TGF-β from T cells. For this bioassay, 293T cells were transduced with (caga)(12) Smad binding element-luciferase along with CD32 (Fc receptor) and CD86. The resulting cells act as artificial antigen presenting cells in the presence of anti-CD3 and produce luciferase in response to biologically active TGF-β. We co-cultured pre-activated murine CD4(+)CD25(-) T cells or CD4(+)CD25(+) T cells with the 293T-caga-Luc-CD32-CD86 reporter cells in the presence of anti-CD3 and IL-2. CD4(+)CD25(-) T cells induced higher luciferase in the reporter cells than CD4(+)CD25(+) T cells. This T cell-produced TGF-β is in a soluble form since T cell culture supernatants contained the TGF-β activity. The TGF-β activity was neutralized with an anti-mouse LAP mAb or an anti-latent TGF-β/pro-TGF-β mAb, but not with anti-active TGF-β Abs. An anti-mouse LAP mAb removed virtually all acid activatable latent TGF-β from the T cell culture supernatant, but not the ability to induce TGF-β signaling in the reporter cells. The induction of TGF-β signaling by T cell culture supernatants was cell type-specific.
CONCLUSIONS/SIGNIFICANCE: A newly developed 293T-caga-Luc-CD32-CD86 reporter cell bioassay demonstrated that murine CD4 T cells produce an unconventional form of TGF-β which can induce TGF-β signaling. This new form of TGF-β contains LAP as a component. Our finding of a new form of T cell-produced TGF-β and the newly developed TGF-β bioassay system will provide a new avenue to investigate T cell function of the immune system.
一般认为 T 细胞不会产生有活性的 TGF-β,因为通过 ELISA 检测未经酸化的上清液中的有活性 TGF-β通常是检测不到的。然而,T 细胞产生的有活性的 TGF-β可能采取一种特殊的形式,这种形式不能通过 ELISA 检测到。
方法/主要发现:我们构建了一种 TGF-β 生物测定法,该方法可以检测 T 细胞中可溶性和膜结合形式的 TGF-β。在这种生物测定法中,293T 细胞转导了(caga)(12)Smad 结合元件-荧光素酶,同时转导了 CD32(Fc 受体)和 CD86。在存在抗-CD3 和 IL-2 的情况下,这些细胞在 293T-caga-Luc-CD32-CD86 报告细胞中充当人工抗原呈递细胞,并响应有生物活性的 TGF-β 产生荧光素酶。我们将预激活的小鼠 CD4(+)CD25(-)T 细胞或 CD4(+)CD25(+)T 细胞与 293T-caga-Luc-CD32-CD86 报告细胞共培养,同时存在抗-CD3 和 IL-2。CD4(+)CD25(-)T 细胞在报告细胞中诱导的荧光素酶活性高于 CD4(+)CD25(+)T 细胞。这种由 T 细胞产生的 TGF-β 呈可溶性形式,因为 T 细胞培养上清液中含有 TGF-β 活性。用抗小鼠 LAP mAb 或抗潜伏 TGF-β/pro-TGF-β mAb 中和 TGF-β 活性,但不能用抗活性 TGF-β Abs 中和。抗小鼠 LAP mAb 从 T 细胞培养上清液中几乎去除了所有可酸化的潜伏 TGF-β,但不能去除诱导报告细胞中 TGF-β 信号的能力。T 细胞培养上清液诱导 TGF-β 信号的作用是细胞类型特异性的。
结论/意义:新开发的 293T-caga-Luc-CD32-CD86 报告细胞生物测定法表明,小鼠 CD4 T 细胞产生一种非常规形式的 TGF-β,可诱导 TGF-β 信号。这种新形式的 TGF-β 包含 LAP 作为一个组成部分。我们发现了一种新的 T 细胞产生的 TGF-β 形式和新开发的 TGF-β 生物测定系统,这将为研究免疫系统中 T 细胞的功能提供一个新的途径。